The Current “Not” State of the Art in Immuno-Oncology Combinations

The promise of immunotherapy, some would argue, has not been fulfilled, and the hopes around follow-on novel agents has been more hype than reality. However, the impact on patients’ lives from checkpoint inhibitors (CPIs) has been profound, as well as from cell therapies, and next gen antibodies.

However, the enthusiasm to find the next Anti-PDx-like agent, some target or modality of significant clinical benefit to be combined with or even displace anti-PDx agents, has been disappointing, with failure and under-performance being the norm. And yet, the unmet need is there. Many patients do not respond, respond well, or respond long-term to CPIs, and so new approaches are desperately needed.

This session, the third in over the past three years of Cancer Progress to address this critical topic, will attempt to expand in the current panel on a range of key elements in this frustrating attempt to take IO to the next level, including: the biology of the TME; clinical development strategies; and basic concepts around combination therapy (additivity, synergy, independent action, etc.).

Attendees will learn:

• Preclinical requirements for attracting Pharma interest.
• Clinical development strategy for optimizing chances of achieving POC/POR
• Some ways to best position a program/platform for value-inflection